Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Calvo

Showing results (81-90 of 140) with videos related to

Pageof 14
Sort By:
Vaccine|November 12, 2019
Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus AnkaraAlejandro Marín-López, Natalia Barreiro-Piñeiro, Sergio Utrilla-Trigo, et al.
Revista Espanola De Cardiologia (English Ed.)|October 4, 2014
Impact of the new American and British guidelines on the management and treatment of dyslipidemia in a Spanish working populationCarlos Brotons, Eva Calvo-Bonacho, Irene Moral, et al.
Chemosphere|January 21, 2015
Urinary polycyclic aromatic hydrocarbon metabolites levels in a representative sample of the Spanish adult population: The BIOAMBIENT.ES projectMónica Bartolomé, Juan José Ramos, Francisco Cutanda, et al.
Atencion Primaria|September 21, 2010
[Effectiveness of a preventive intervention strategy based on structured telephone interviews in a working population with a moderate to high cardiovascular risk]Martha Cabrera Sierra, Eva Calvo Bonacho, Ángel García García, et al.
Plos One|February 8, 2011
A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse modelJavier Castillo-Olivares, Eva Calvo-Pinilla, Isabel Casanova, et al.
Antiviral Research|July 25, 2014
VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) miceAlejandro Marín-López, Iria Otero-Romero, Francisco de la Poza, et al.
European Journal of Preventive Cardiology|April 10, 2021
Prediction of fatal and non-fatal cardiovascular events in young and middle-aged healthy workers: The IberScore modelCarlos Fernández-Labandera, Eva Calvo-Bonacho, Pedro Valdivielso, et al.
The Science of the Total Environment|November 7, 2021
COVID-19 lockdown moderately increased oligotrophy at a marine coastal siteMaria Montserrat Sala, Francesc Peters, Marta Sebastián, et al.
Frontiers in Immunology|July 29, 2024
Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virusLuis Jiménez-Cabello, Sergio Utrilla-Trigo, Eva Calvo-Pinilla, et al.
Environment International|January 10, 2019
Associations of multiple exposures to persistent toxic substances with the risk of hyperuricemia and subclinical uric acid levels in BIOAMBIENT.ES studyJuan Pedro Arrebola, Juan José Ramos, Mónica Bartolomé, et al.
Pageof 14

Showing results (81-90 of 140) with videos related to

Sort By:
Pageof 14
Vaccine|November 12, 2019
Cross-protective immune responses against African horse sickness virus after vaccination with protein NS1 delivered by avian reovirus muNS microspheres and modified vaccinia virus AnkaraAlejandro Marín-López, Natalia Barreiro-Piñeiro, Sergio Utrilla-Trigo, et al.
Revista Espanola De Cardiologia (English Ed.)|October 4, 2014
Impact of the new American and British guidelines on the management and treatment of dyslipidemia in a Spanish working populationCarlos Brotons, Eva Calvo-Bonacho, Irene Moral, et al.
Chemosphere|January 21, 2015
Urinary polycyclic aromatic hydrocarbon metabolites levels in a representative sample of the Spanish adult population: The BIOAMBIENT.ES projectMónica Bartolomé, Juan José Ramos, Francisco Cutanda, et al.
Atencion Primaria|September 21, 2010
[Effectiveness of a preventive intervention strategy based on structured telephone interviews in a working population with a moderate to high cardiovascular risk]Martha Cabrera Sierra, Eva Calvo Bonacho, Ángel García García, et al.
Plos One|February 8, 2011
A modified vaccinia Ankara virus (MVA) vaccine expressing African horse sickness virus (AHSV) VP2 protects against AHSV challenge in an IFNAR -/- mouse modelJavier Castillo-Olivares, Eva Calvo-Pinilla, Isabel Casanova, et al.
Antiviral Research|July 25, 2014
VP2, VP7, and NS1 proteins of bluetongue virus targeted in avian reovirus muNS-Mi microspheres elicit a protective immune response in IFNAR(-/-) miceAlejandro Marín-López, Iria Otero-Romero, Francisco de la Poza, et al.
European Journal of Preventive Cardiology|April 10, 2021
Prediction of fatal and non-fatal cardiovascular events in young and middle-aged healthy workers: The IberScore modelCarlos Fernández-Labandera, Eva Calvo-Bonacho, Pedro Valdivielso, et al.
The Science of the Total Environment|November 7, 2021
COVID-19 lockdown moderately increased oligotrophy at a marine coastal siteMaria Montserrat Sala, Francesc Peters, Marta Sebastián, et al.
Frontiers in Immunology|July 29, 2024
Co-expression of VP2, NS1 and NS2-Nt proteins by an MVA viral vector induces complete protection against bluetongue virusLuis Jiménez-Cabello, Sergio Utrilla-Trigo, Eva Calvo-Pinilla, et al.
Environment International|January 10, 2019
Associations of multiple exposures to persistent toxic substances with the risk of hyperuricemia and subclinical uric acid levels in BIOAMBIENT.ES studyJuan Pedro Arrebola, Juan José Ramos, Mónica Bartolomé, et al.
Pageof 14